ViroPharma Incorporated Completes Acquisition of DuoCort Pharma AB
by RealPTC Expert
ViroPharma Incorporated today announced that it completed its acquisition of DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy. The acquisition of Duocort Pharma AB further expands ViroPharma's orphan disease commercial product pipeline. ViroPharma has paid an upfront closing cost of 220 million Swedish kroner (SEK) or $33.6 million in US dollars (USD). Additionally, there are contingent milestone payments of up to 860 million SEK or approximately $131 million USD associated with manufacturing, sales thresholds and territory expansion.
Subscribe to:
Post Comments (Atom)
0 comments:
Leave a Comment